Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at TD Cowen to a "hold" rating.
KROS vs. ARGX: Which Stock Is the Better Value Option? [Yahoo! Finance]
Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]
Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]